Indivior (INDV) on Monday said that it will cancel its secondary listing on the London Stock Exchange, effective July 25, ...

(Reuters) -Pharma firm Indivior said on Monday it would cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Indivior said it would cancel its listing on the London Stock Exchange and keep its primary listing on New York City's Nasdaq stock exchange.

U.S. steel stocks, more. Wall Street sees more weakness ahead for U.S. dollar. Indivior to delist from London Stock Exchange, ...

Investing.com -- Indivior (LON: INDV) on Monday said it will delist from the London Stock Exchange (LON: LSEG) on July 25, ...

Indivior is set to delist from the London Stock Exchange after a sharp decline in the value of its shares and a management ...

Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, ...

Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange ...

Australian biotech TekCyte Limited appointed a new co-CEO leadership team consisting of Tony Simula, TekCyte’s founding CEO, as well as Tara James, a commercial strategist and founder of Small and ...

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...